- Phase 1
- Phase 2
- Phase 3
- Filed
- Approved
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Approved / Authorized Date: 2023-11-09FDA accelerated approval for individuals 18+ at high risk of chikungunya virus exposure |
| EMA (Europe) | Approved / Authorized Date: 2024-06-28EMA approved for active immunization of individuals 18+ |
| Health Canada | Approved / Authorized Date: 2024-06-14Health Canada approved |
| TGA (Australia) | Under Regulatory Review Date: 2024-09-01TGA submission under evaluation |
Progress and adoption outlook
Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Regulator-confirmed status date in at least one jurisdiction.
- Preclinical
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Submitted to a regulator
- Under regulatory review
- Approved / authorised
- Recommended for routine use
Current position: Approved / authorised
| Jurisdiction | Status in the record | Submission | Regulator decision | Earliest routine use |
|---|---|---|---|---|
| United StatesFDA (CBER) · ACIP (CDC) | approved (2023-11-09, regulator confirmed) | — | 2023-112023-11 to 2023-11 | — |
| European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others) | approved (2024-06-28, regulator confirmed) | — | 2024-062024-06 to 2024-06 | — |
| CanadaHealth Canada · NACI | approved (2024-06-14, regulator confirmed) | — | 2024-062024-06 to 2024-06 | — |
| United KingdomMHRA · JCVI | no jurisdiction-specific filing known | The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used. | ||
| AustraliaTGA · ATAGI | under review (2024-09-01, company estimate) | TGA registration-timeframe pages timed out on 2026-10-24; no target is used. | ||
| JapanPMDA / MHLW · MHLW immunisation subcommittee | no jurisdiction-specific filing known | PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure. | ||
| WHO prequalificationWHO Prequalification · SAGE | no jurisdiction-specific filing known | WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used. | ||
Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.
Scientific Profile & Documentation
- Platform Architecture
- Live attenuated
- Lead Developer
- Valneva
- Next Expected Milestone
- Post-marketing safety surveillance; adolescent trial data readout
- Analyst & Development Notes
- Required edge case: approval is not always terminal. A licensed vaccine can be suspended or restricted post-approval. Re-verify live FDA/EMA status before publishing clinical implications.
- Primary Source Documentation
- FDA vaccines licensed / safety communications (verify live) →
- Additional Sources & Literature
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.
Milestone Overview
-
Stage VerificationApproved / Licensed confirmed as of 2026-08-01.
-
Target MilestonePost-marketing safety surveillance; adolescent trial data readout
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.